Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood

Background While programmed cell death receptor 1 (PD-1) blockade treatment has revolutionized treatment of patients with melanoma, clinical outcomes are highly variable, and only a fraction of patients show durable responses. Therefore, there is a clear need for predictive biomarkers to select pati...

Full description

Bibliographic Details
Main Authors: David Gomez-Cabrero, Rolf Kiessling, Yago Pico de Coaña, Maria Wolodarski, Johan Hansson, Jesper Tegner, Soudabeh Rad Pour, Xavier Martinez Demorentin, Jeroen Melief, Manjula Thimma
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002171.full

Internet

https://jitc.bmj.com/content/9/5/e002171.full

Similar Items